Amylyx to present Phase 3 LUCIDITY topline data for avexitide in post-bariatric hypoglycemia at ObesityWeek 2026

• Amylyx scheduled Phase 3 LUCIDITY topline results for avexitide in post-bariatric hypoglycemia for presentation at ObesityWeek 2026.
• The data were not presented yet; the late-breaking oral session is set for Nov. 15, 2026, in Washington, D.C.
• Management previously disclosed positive topline results, supporting avexitide’s efficacy and safety profile in the pivotal trial.
• Avexitide targets the GLP-1 pathway to curb inappropriate insulin release, aiming to stabilize blood sugar in a condition without an FDA-approved therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610060800BIZWIRE_USPR_____20261006_BW471792) on October 06, 2026, and is solely responsible for the information contained therein.